Ann Oncol. 2016 Dec 5. [Epub ahead of print] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curiglia...
5th ESO-ESMO international consensus guidelines for advanced breastcancer (ABC 5) † , Annals of Oncology (2020), doi: https://doi.org/10.1016/j.annonc.2020.09.010.This is a PDF file of an article that has undergone enhancements after acceptance, such as the additionof a cover page and...
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.EBSCO_AspAnnals of Oncology
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) † . Ann Oncol. 2014;25(10):1871–88. Central... Cardoso,Costa,Norton,... 被引量: 0发表: 0年 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of ...
Table 4. Assessment and treatment general guidelines in advanced breast cancer GuidelinesLoE, GoRConsensus In ABC, age alone is not a reason to prescribe more aggressive therapy and International Consensus Guidelines for management of advanced breast cancer must be applied (ABC 4 ESO–ESMO, NCCN gui...
[4] Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. [5] Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer...
[10].Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer. 2016 Sep;23(5):771-9. ...
2025年欧洲肿瘤内科学会(ESMO)年会/大会将于2025年10月17-21日在德国柏林举行,会议由欧洲肿瘤内科学会(ESMO)主办。欧洲肿瘤内科学会年会(ESMO大会)是欧洲最负盛名和最具影响力的肿瘤学会议,每年都有超过30,000名专业人士参加会议;届时来自世界各地的临床医生、研究人员、患者倡导者、记者和制药业人士将齐聚一堂,一...
[11]Kim JY, Oh JM, Park YH, Ahn JS, Im YH. Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Ad...
[6] Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (D...